Tecos Trial Design
JANUVIA® (sitagliptin) offers people aged 65 and over with T2DM the reassurance of an established renal and CV safety profile1
Many older people with T2DM may experience renal damage that can lead to increased cardiovascular risk.1 TECOS explored the safety of JANUVIA in the CV safety trial of DPP-4 inhibitors in T2DM vs. usual care alone.1
Key trial design details:
- Randomised double blind CV safety trial1
- Over 14,000 patients1
- 3 years median follow up1
When added to usual care, JANUVIA demonstrated:
No increased CV risk1
Primary composite endpoint of CV death, nonfatal MI, nonfatal stroke,nonfatal myocardial infarction, or hospitalisation for unstable angina (PP HR 0.98 (95% CI: 0.88-1.09), p<0.001 for non-inferiority vs.placebo, n=14,523)1
No increased risk of hospitalisation for heart failure1
ITT HR 1.00 (95% CI: 0.83-1.20), p=0.985
PP: per protocol; HR: hazard ratio; CI: confidence interval;
Green et al, 20151
TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) is a randomised double blind controlled CV safety trial, comparing JANUVIA and placebo when added to usual care in 14,671 patients with type 2 diabetes and established cardiovascular disease. Median follow-up was 3.0 years (interquartile range, 2.3 to 3.8, maximum, 5.7).
Enrolled 14,735 patients aged >50 years with type 2 diabetes and a history of cardiovascular disease
Both groups treated to individually appropriate HbA1c targets with the aim of no difference in the glycaemic control between arms**
•Prior antihyperglycaemic monotherapy or dual therapy† was continued after randomisation.
• Additional diabetes medications,† including insulin (excluding other DPP-4 inhibitors and GLP-1 receptor agonists), could have been added based on usual care to target individualised HbA1c goals according to local guidelines.
* Starting dose of once-daily sitagliptin was 100 mg or 50 mg for patients with eGFR 30–50 mL/min/1.73m²; if eGFR fell to <30 mL/min/1.73m², the dose was reduced to once-daily sitagliptin 25 mg; if eGFR showed sustained recovery, dose was up-titrated.
**During the study there was a small difference of HbA1c (least-square mean difference for sitagliptin vs. placebo. -0.29%; 95% confidence CI, -0.32 to -0.27, p<0.001).
† Antihyperglycaemic medication could have included metformin, sulphonylurea, pioglitazone, or insulin with or without metformin, excluding other DPP-4 inhibitors and GLP-1 RAs.
- Green JB et al. N Engl J Med. 2015;373(3):232–242.